Table 2.
Meta-analyses of MVD and survival of HNSCC.
| N of studies | Model | HR (95% CI) | Log rank P | Heterogeneity (I2, P) | |
|---|---|---|---|---|---|
| Total OS | 11 | Random | 1.663 (1.236, 2.237) | 0.001 | 77.1%, <0.001 |
| Total PFS | 7 | Random | 2.069 (1.281, 3.343) | 0.003 | 78.4%, <0.001 |
| European OS | 5 | Random | 1.979 (1.174, 3.334) | 0.010 | 85.7%, <0.001 |
| North American OS | 3 | Fixed | 1.049 (0.805, 1.367) | 0.725 | 13.9%, 0.313 |
| Asian OS | 3 | Fixed | 2.530 (1.534, 4.174) | <0.001 | 20.6%, 0.284 |
| Median/mean age ≥ 60 OS | 5 | Random | 2.238 (1.213, 4.130) | 0.010 | 67.3%, 0.016 |
| Median/mean age ≥60 PFS | 5 | Random | 2.728 (1.492, 4.986) | 0.001 | 68.2%, 0.014 |
| Pharynx OS | 4 | Random | 1.390 (0.993, 1.945) | 0.055 | 73.8%, 0.010 |
| Oral cavity OS | 2 | Random | 2.748 (1.053, 7.170) | 0.039 | 54.1%, 0.140 |
| CD105 OS | 4 | Fixed | 2.916 (1.945, 4.370) | <0.001 | 32.2%, 0.219 |
| Surgery OS | 7 | Random | 2.578 (1.522, 4.365) | <0.001 | 61.5%, 0.016 |
| Chemo-radiotherapy OS | 4 | Random | 1.176 (0.917, 1.508) | 0.202 | 67.2%, 0.027 |
HR: hazard ratio; CI: confidence interval; OS: overall survival; PFS: progression-free survival; N: number.